Physician

Adarsha Shrestha, M.D.

According to 2025 Medicare claims, Adarsha Shrestha, M.D. (NPI: 1548426398) practices nephrology in the Port St. Lucie, FL market, with the plurality of this provider's patient population coming from St. Lucie, FL. This provider's primary affiliated billing organization is MARTIN MEMORIAL MEDICAL CENTER INC (NPI: 1194790055; TIN: 590637874) and primary practice location at 34994-2346. Shrestha is affiliated with the Cleveland Clinic Florida Integrated Health (ACO ID: A3588), participating under the MSSP model.

Shrestha's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 700 traditional Medicare patients, billed 2,273 HCPCS/CPT codes, and received $202,128 in Medicare payments. The top billing code was 99222 (Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes). Part D data shows 2,531 prescription claims across 469 beneficiaries totaling $88,251 in drug costs, led by Farxiga (Dapagliflozin Propanediol). DME data shows 25 claims. Open Payments data shows 2 records totaling $244. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has changed little. Concurrently, Part D prescription costs have moved up and down with repeated peaks and valleys, starting at $84,701 and ending at $88,251. In contrast, DME billing represents a smaller volume and changed little.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	679	2,508	$205,730
2016	734	2,980	$215,696
2017	775	2,878	$242,972
2018	769	2,685	$231,992
2019	770	2,676	$224,462
2020	708	2,726	$211,934
2021	727	2,430	$235,004
2022	723	2,479	$221,116
2023	652	1,601	$167,583
2024	700	2,273	$202,128

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	287	1,906	$84,701
2016	304	2,117	$92,943
2017	320	2,028	$114,013
2018	351	2,059	$105,969
2019	376	2,282	$124,337
2020	367	2,294	$92,003
2021	394	2,320	$102,090
2022	440	2,397	$67,277
2023	473	2,598	$56,950
2024	469	2,531	$88,251

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	51	$2,156
2016	N/R	44	$1,964
2017	N/R	69	$3,128
2018	N/R	139	$6,570
2019	N/R	139	$4,509
2020	N/R	161	$5,668
2021	N/R	93	$2,146
2022	N/R	61	$1,626
2023	N/R	N/R	N/R
2024	N/R	25	$555

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99222	Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes	113	124	$107
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	277	472	$100
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	140	167	$71
99232	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes	185	480	$63
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	326	411	$14

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Farxiga	Dapagliflozin Propanediol	13	930	$16,857
Sevelamer Carbonate	Sevelamer Carbonate	27	1,860	$5,809
Doxazosin Mesylate	Doxazosin Mesylate	207	17,160	$3,106
Potassium Citrate Er	Potassium Citrate	22	1,478	$2,606
Allopurinol	Allopurinol	348	30,413	$2,473

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J7507	Tacrolimus, immediate release, oral, 1 mg	N	N/R	11	$380
Q0512	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period	N	N/R	14	$176

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	2	$244	CALLIDITAS THERAPEUTICS US INC.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Adarsha Shrestha, M.D.?

Tedicare shows public-source Medicare data for Adarsha Shrestha, M.D. (NPI 1548426398), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Adarsha Shrestha, M.D. have ACO affiliation data?

Adarsha Shrestha, M.D. is shown with ACO affiliation data for Cleveland Clinic Florida Integrated Health (MSSP, ACO ID A3588).

What billing organization is linked to Adarsha Shrestha, M.D.?

Adarsha Shrestha, M.D. is linked to MARTIN MEMORIAL MEDICAL CENTER INC (billing NPI 1194790055) in the available physician profile data.

Does Adarsha Shrestha, M.D. have Open Payments data?

Adarsha Shrestha, M.D. has 2 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.